Adaptive Biotechnologies
ADPTAdaptive Biotechnologies is a commercial-stage biotechnology company that decodes the adaptive immune system to transform disease diagnosis and treatment.
Earnings
Next report
Date not yet announcedValuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Adaptive Biotechnologies is a commercial-stage biotechnology company that decodes the adaptive immune system to transform disease diagnosis and treatment. The company utilizes a proprietary immune medicine platform combining high-throughput sequencing, computational biology, and machine learning to translate complex immunomics data into clinical products and research services.
Competitive position
A leader in NGS-based immune repertoire sequencing with the first FDA-authorized MRD test for lymphoid malignancies.
GeographiesUnited States, Europe, Canada, Australia, Japan
Customer segmentsHealthcare providers, Pharmaceutical companies, Research institutions
Business modelDiagnostic services, Data licensing, Research as a service, B2B, B2C
SuppliersNext-generation sequencing instrument providers, Specialized chemical and reagent suppliers, Cloud computing and AI infrastructure, Blood and bone marrow sample collection sites
CustomersHospitals and cancer centers, Biopharmaceutical R&D divisions, Health insurance payors, Academic researchers
CountryUnited States of America
Listed2019
Employees709.0
CEOChad Robins
SectorHealthcare
IndustryBiotechnology
Websiteadaptivebiotech.com
FilingsSEC EDGAR
Questions, answered.
- What is Adaptive Biotechnologies's market cap?
- Adaptive Biotechnologies (ADPT) has a market capitalization of $3.6B and trades on NASDAQ.
- What is Adaptive Biotechnologies's revenue and profitability?
- Adaptive Biotechnologies generated $295.4M in trailing twelve-month revenue with a net loss of $49.7M, representing a net margin of -16.8%. Gross margin stands at 75.3%, with free cash flow of -$31.0M. These figures are based on the Q1 2026 filing.
- Who are Adaptive Biotechnologies's competitors?
- Adaptive Biotechnologies's key competitors include Natera, Inc., Guardant Health, Inc., Rezolute, Inc. Common Stock (NV), and others. These companies compete in similar markets and product categories.
- Who does Adaptive Biotechnologies partner with?
- Adaptive Biotechnologies's notable partners include Pfizer Inc., Epic Systems Corporation, Flatiron Health, Inc., and others.
- What subsidiaries does Adaptive Biotechnologies have?
- Adaptive Biotechnologies's subsidiaries include Sequenta, Inc., Digital Biotechnologies, Inc., Imdaptive, Inc., and others.
- Where is Adaptive Biotechnologies headquartered?
- Adaptive Biotechnologies is headquartered in United States of America and employs approximately 709 people. It has been publicly traded since 2019.
